Indivior Pharmaceuticals (INDV) Non-Current Assets (2021 - 2026)

Indivior Pharmaceuticals' Non-Current Assets history runs 6 years deep, the most recent figure standing at $530.0 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 7.72% year-over-year to $530.0 million in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 830.04% increase from a year earlier, with the FY2025 full-year figure at $549.0 million, up 12.27% from the prior year.
• Non-Current Assets declined to $530.0 million in Q1 2026 per INDV's latest filing, from $549.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $549.0 million in Q4 2025 and bottomed at -$1.3 billion in Q4 2022.
• The 5-year median for Non-Current Assets is $497.5 million (2023), against an average of $287.1 million.
• Across the five-year window, Non-Current Assets soared 139.79% in 2023 and retreated 2.4% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at -$1.3 billion in 2022, then soared by 139.79% to $501.0 million in 2023, then fell by 2.4% to $489.0 million in 2024, then climbed by 12.27% to $549.0 million in 2025, then retreated by 3.46% to $530.0 million in 2026.
• Per Business Quant, the three latest INDV Non-Current Assets figures stand at $530.0 million (Q1 2026), $549.0 million (Q4 2025), and $494.0 million (Q3 2025).